MedKoo Cat#: 596883 | Name: MEN 10207

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MEN10207 is a peptide neurokinin-2 (NK2) receptor antagonist.

Chemical Structure

MEN 10207
MEN 10207
CAS#126050-12-2 (free base)

Theoretical Analysis

MedKoo Cat#: 596883

Name: MEN 10207

CAS#: 126050-12-2 (free base)

Chemical Formula: C57H68N14O10

Exact Mass: 1108.5243

Molecular Weight: 1109.25

Elemental Analysis: C, 61.72; H, 6.18; N, 17.68; O, 14.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
MEN 10207; MEN-10207; MEN10207;
IUPAC/Chemical Name
(6S,9R,12R,15S,18R,21S,24S)-9,12,18-tris((1H-indol-3-yl)methyl)-1,24-diamino-6-carbamoyl-21-(4-hydroxybenzyl)-1-imino-15-isopropyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazahexacosan-26-oic acid
InChi Key
RLHLZLAKTUPWES-PEURKWGASA-N
InChi Code
InChI=1S/C57H68N14O10/c1-30(2)49(71-55(80)47(25-34-29-65-42-15-8-5-12-38(34)42)69-52(77)44(22-31-17-19-35(72)20-18-31)67-51(76)39(58)26-48(73)74)56(81)70-46(24-33-28-64-41-14-7-4-11-37(33)41)54(79)68-45(23-32-27-63-40-13-6-3-10-36(32)40)53(78)66-43(50(59)75)16-9-21-62-57(60)61/h3-8,10-15,17-20,27-30,39,43-47,49,63-65,72H,9,16,21-26,58H2,1-2H3,(H2,59,75)(H,66,78)(H,67,76)(H,68,79)(H,69,77)(H,70,81)(H,71,80)(H,73,74)(H4,60,61,62)/t39-,43-,44-,45+,46+,47+,49-/m0/s1
SMILES Code
N=C(N)NCCC[C@@H](C(N)=O)NC([C@@H](CC1=CNC2=C1C=CC=C2)NC([C@@H](CC3=CNC4=C3C=CC=C4)NC([C@H](C(C)C)NC([C@@H](CC5=CNC6=C5C=CC=C6)NC([C@H](CC7=CC=C(O)C=C7)NC([C@H](CC(O)=O)N)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,109.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mussap CJ, Stamatakos C, Burcher E. Radioligand binding, autoradiographic and functional studies demonstrate tachykinin NK-2 receptors in dog urinary bladder. J Pharmacol Exp Ther. 1996 Oct;279(1):423-34. PubMed PMID: 8859022. 2: Burcher E, Zeng XP, Strigas J, Geraghty DP, Lavielle S. Tachykinin receptors in guinea-pig airways: characterization using selective ligands. Can J Physiol Pharmacol. 1995 Jul;73(7):915-22. PubMed PMID: 8846430. 3: Medeiros MD, Turner AJ. Metabolic stability of some tachykinin analogues to cell-surface peptidases: roles for endopeptidase-24.11 and aminopeptidase N. Peptides. 1995;16(3):441-7. PubMed PMID: 7651897. 4: Parrish MB, Rainsford KD, Johnson DM, Daniel EE. NK1 receptors mediated release of 6-keto-PGF1 alpha from the ex vivo perfused canine ileum. J Pharmacol Exp Ther. 1994 Oct;271(1):39-47. PubMed PMID: 7525925. 5: Zeng XP, Burcher E. Use of selective antagonists for further characterization of tachykinin NK-2, NK-1 and possible "septide-selective" receptors in guinea pig bronchus. J Pharmacol Exp Ther. 1994 Sep;270(3):1295-300. PubMed PMID: 7523658. 6: Wiesenfeld-Hallin Z, Luo L, Xu XJ, Maggi CA. Differential effects of selective tachykinin NK2 receptor antagonists in rat spinal cord. Eur J Pharmacol. 1994 Jan 4;251(1):99-102. PubMed PMID: 8137876. 7: Zeng XP, Lavielle S, Burcher E. Evidence for tachykinin NK-2 receptors in guinea-pig airways from binding and functional studies, using [125I]-[Lys5,Tyr(I2)7,MeLeu9,Nle10]-NKA(4-10). Neuropeptides. 1994 Jan;26(1):1-9. PubMed PMID: 7512696. 8: Kudlacz EM, Logan DE, Shatzer SA, Farrell AM, Baugh LE. Tachykinin-mediated respiratory effects in conscious guinea pigs: modulation by NK1 and NK2 receptor antagonists. Eur J Pharmacol. 1993 Sep 7;241(1):17-25. PubMed PMID: 7693493. 9: Culman J, Tschöpe C, Picard P, Prat A, Regoli D, Couture R, Unger T. In vivo characterization of tachykinin receptors responsible for the central cardiovascular effects of substance P and neurokinin A. Regul Pept. 1993 Jul 2;46(1-2):364-6. PubMed PMID: 7692538. 10: Mapp CE, Boniotti A, Papi A, Chitano P, Coser E, Di Stefano A, Saetta M, Ciaccia A, Fabbri LM. The effect of compound 48/80 on contractions induced by toluene diisocyanate in isolated guinea-pig bronchus. Eur J Pharmacol. 1993 Jun 1;248(1):67-73. PubMed PMID: 7687959. 11: Luo L, Wiesenfeld-Hallin Z. Low-dose intrathecal clonidine releases tachykinins in rat spinal cord. Eur J Pharmacol. 1993 Apr 22;235(1):157-9. PubMed PMID: 7686104. 12: Burcher E, Badgery-Parker T, Zeng XP, Lavielle S. Characterisation of a novel, selective radioligand, [125I][Lys5,Tyr(I2)7,MeLeu9,Nle10]neurokinin A-(4-10), for the tachykinin NK2 receptor in rat fundus. Eur J Pharmacol. 1993 Mar 23;233(2-3):201-7. PubMed PMID: 8385622. 13: Tschöpe C, Picard P, Culman J, Prat A, Itoi K, Regoli D, Unger T, Couture R. Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat. Br J Pharmacol. 1992 Nov;107(3):750-5. PubMed PMID: 1335337; PubMed Central PMCID: PMC1907752. 14: Black JL, Diment LM, Alouan LA, Johnson PR, Armour CL, Badgery-Parker T, Burcher E. Tachykinin receptors in rabbit airways--characterization by functional, autoradiographic and binding studies. Br J Pharmacol. 1992 Oct;107(2):429-36. PubMed PMID: 1384914; PubMed Central PMCID: PMC1907857. 15: Reddix RA, Cooke HJ. Neurokinin 1 receptors mediate substance P-induced changes in ion transport in guinea-pig ileum. Regul Pept. 1992 Jun 11;39(2-3):215-25. PubMed PMID: 1279753. 16: Xu XJ, Dalsgaard CJ, Maggi CA, Wiesenfeld-Hallin Z. NK-1, but not NK-2, tachykinin receptors mediate plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw: demonstrated with the NK-1 antagonist CP-96,345 and the NK-2 antagonist Men 10207. Neurosci Lett. 1992 May 25;139(2):249-52. PubMed PMID: 1319017. 17: Taylor SJ, Kilpatrick GJ. Characterization of histamine-H3 receptors controlling non-adrenergic non-cholinergic contractions of the guinea-pig isolated ileum. Br J Pharmacol. 1992 Mar;105(3):667-74. PubMed PMID: 1352720; PubMed Central PMCID: PMC1908443. 18: Henderson AK, Yamamura HI, Maggi CA, Buck SH, Van Giersbergen PL, Roeske WR. Demonstration of a neurokinin A receptor subtype in transfected fibroblasts. Eur J Pharmacol. 1992 Feb 13;225(2):175-8. PubMed PMID: 1312943. 19: Rovero P, Quartara L, Astolfi M, Patacchini R, Giachetti A, Maggi CA. Structure-activity study of the C-terminal residue of MEN 10207 tachykinin antagonist. Peptides. 1992 Jan-Feb;13(1):207-8. PubMed PMID: 1320265. 20: Mapp CE, Fabbri LM, Boniotti A, Maggi CA. Prostacyclin activates tachykinin release from capsaicin-sensitive afferents in guinea-pig bronchi through a ruthenium red-sensitive pathway. Br J Pharmacol. 1991 Sep;104(1):49-52. PubMed PMID: 1723916; PubMed Central PMCID: PMC1908289.